Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chloral betaine is a sedative-hypnotic agent consisting of a chemical complex of chloral hydrate and betaine. It was developed to provide a stable, solid dosage form of chloral hydrate, which is otherwise a volatile solid with an unpleasant taste and irritant properties. Upon ingestion, the complex dissociates into its constituent parts; the chloral hydrate is then rapidly metabolized by alcohol dehydrogenase into trichloroethanol, the active metabolite responsible for the drug's pharmacological effects. Trichloroethanol acts as a positive allosteric modulator of the GABA-A receptor, enhancing inhibitory neurotransmission in the central nervous system. Historically, chloral betaine was used for the short-term treatment of insomnia and as a preoperative sedative, particularly in elderly or mentally disturbed patients, though it has largely been replaced by safer alternatives such as benzodiazepines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chloral betaine.